We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
UK’s National Institute for Health and Care Excellence (NICE) has approved Amgen’s new anti-cancer treatment carflizomib for multiple myeloma patients on the National Health Service (NHS).